Mena Abdel-Nour is an Analyst at Bloom Burton and joined in August 2019. Mena’s role is to provide scientific due diligence of life science and healthcare companies, as well as supporting the growth and monetization of life science technology companies in the Canadian healthcare ecosystem.
Prior to joining Bloom Burton, Mena has pursued the commercialization and development of novel therapeutics for inflammatory disease based on his research published in the journal, Science, and has supported entrepreneurial healthcare opportunities through the Translational Research Program at the University of Toronto. Mena also brings experience performing due diligence for the Maple Leaf Angels and York Angels investing groups.
Mena completed his PhD at the University of Toronto where he focused on the biochemistry and molecular biology of innate immunology. His PhD was completed in collaboration with Public Health Ontario studying the biofilm formation of Legionella pneumophila.